Disclosed is the use of 10 to 40 mg of oxycodone hydrochloride and of 5 to 20 mg naloxone hydrochloride with oxycodone hydrochloride and naloxone hydrochloride being present in a ratio of 2:1 by weight in the manufacture of a controlled release pharmaceutical dosage form for the treatment of moderate to severe pain and reducing the severity of opioid bowel dysfunction syndromes and reducing the incidence of diarrhea as elicited naloxone typical adverse event in a population that is sensitive to naloxone induced diarrhea.
